would be 13%. 8.9,12 However, since a PRU test is usually performed during admission for ACS, it was estimated that 32% of patients would receive ticagrelor. 10 It was expected that, after 1 year, all patients would discontinue DAPT, and be denied the additional therapeutic effect of these drugs thereafter. The incidence of non-fatal MI and non-fatal stroke, starting from the second year, was consistent with published epidemiological data. 13, 14 Mortality of patients was calculated on the basis of epidemiological data for Russia, with relative risk adjustments made for various cardiovascular events. 15 Costs for stroke treatment were calculated on the basis of compulsory medical insurance tariffs in St Petersburg for 2014, with consideration for severity of the disease in the Russian population (minor stroke, modified Rankin scale [mRS] 0-2: 51%; moderate stroke, mRS 3-4:
19%; severe stroke, mRS 5: 1%; fatal stroke: 29%). This totalled US$1,468. 16, 17 Death in the acute phase of MI was 16%, in line with Russian national statistics, and stroke death was 29%. [17] [18] [19] Costs for treatment of non-fatal MI, taking into account the early rehabilitation period, were US$2,440, while the average cost for bleeding events amounted to US$245.
The cost of generic clopidogrel and ticagrelor conformed with the average-weighted cost of public procurement in 2013, with clopidogrel working out at US$206 a year and ticagrelor at US$1,222. The cost of performing a PRU test in the course of modelling was set at US$33.
The impact of cardiovascular events on quality of life was set from published reports. 20, 21 The cost and life expectancy were discounted at 3.5% per year. With regards to cost-effectiveness, WHO recommendations applied. In short, an acceptable level of additional costs per 1 year of life with consideration for quality (quality-adjusted life year [QALY]) should not exceed three times the gross domestic product (GDP) per capita. 22, 23 When the value of additional costs per 1 QALY does not exceed national GDP per capita, the proposed intervention is considered to be economically highly effective and should be widely used in clinical practice. The study design is shown in Figure 1 and main modelling parameters in Table 2 .
Results
Providing early, guided DAPT will prevent five MIs and six deaths per 1,000 patients compared to uniform prescription of generic clopidogrel ( Table 3) . The costs per one additional year of survival with a tailored strategy (US$12,550) was only slightly higher (US$12,440) than when taking the uniform approach. The costs for one additional QALY were US$14,460, and US$16,993 respectively.
The total predictive value of costs per patient was 32% lower with guided strategy than with uniformed ticagrelor in all patients. Blindly prescribing ticagrelor without a platelet test increases the affiliated cost more than twice compared to generic clopidogrel. Since the GDP per capita for Russia in 2013 was US$15,500, performing a PRU test in patients post ACS and prescribing DAPT, dependent on the assay results, can be considered as a highly effective economic strategy ( Table 4 ).
Discussion
This analysis revealed that assessment of HRPR with P2Y 12 assay in triaging DAPT for post-ACS patients for 1 year is a cost-effective strategy, with a lower financial burden than the routine administration of more expensive antiplatelet agents. This is important since inexpensive generic clopidogrel, including local formulations, are consistently growing and dominate Russian pharmaceutical market. In contrast, branded ticagrelor cost about six times more, so would incur an obvious financial burden.
There are certain limitations. Firstly, many considerations are based on the results of the PLATO trial. Since low-risk patients and medically managed patients were not included in our model, economic considerations may be attributed to ST-segment elevation ACS only if they were planned to undergo primary percutaneous coronary intervention. Therefore, it is difficult to apply this model to the entire ACS cohort.
In addition, in PLATO, 46% of the patients in the ticagrelor group received clopidogrel before randomisation and, within 24 hours before or after randomisation, 34% of the patients in this group received a Cost-effectiveness of Guided Antiplatelet Therapy 
Implantation and of Treatment Interruption versus Continuation One
Year after Stenting (ARCTIC) trial, did not include the benefits of monitoring HRPR during DAPT and to guide dosing strategy. 24 Another shortcoming is that the current analysis covered generic clopidogrel, specifically the Russian pharmaceutical market, while branded clopidogrel was used in PLATO.
Conclusion
Within the Russian healthcare system assessment of platelet reactivity with VerifyNow P2Y 12 assay in patients with ACS followed by DAPT modification is a more cost-effective approach to reducing treatment costs then the routine use of newer antiplatelet agents. 
